"TPA eligible" INR Value
Hi Everyone,
We are working on implementing PTINR with the Hemochron SigElite in our Emergency Department for stroke protocol. Validations went swimmingly as per manufacturer's claim/product
insert, however the INR & Plasma Equiv values do not compare well to the laboratory (we use the IL Tops). We concluded that the POCT INR will have to have a different reference range.
Our stroke protocol uses a series of criteria for a patient to receive TPA - one of which is INR. We anticipate the physicians asking for us to provide them a new specific TPA cutoff
value, but there isn't a set bias when comparing the SigElite and Tops.
My pathologist has asked me to reach out and ask what other institutions are doing with SigElite in their stroke protocol.
Is anyone currently using the SigElite Citrated PTINR and would you be willing to provide your TPA eligible INR value? This is not the cutoff value to confirm with the lab, but the
value physicians use to give TPA. Please feel free to contact me offline.
Blessings,
Carrie Jo Szablowski
MLS (ASCP)CM, CLS
Clinical Laboratory Scientist Technical Resource
Point of Care Department (805) 569 - 7859
Pacific Diagnostic Laboratories
Santa Barbara Cottage Hospital
Technical support:
POCTLab@sbch.org
CH Disclaimer: This electronic mail message is intended exclusively for the individual or entity to which it is addressed. This message, together with any attachment, may contain confidential and
privileged information. Any views, opinions or conclusions expressed in this message are those of the individual sender and do not necessarily reflect the views of Cottage Health, its subsidiaries or affiliates. This document may also contain information covered
under the Health Insurance Portability and Accountability Act (HIPAA, PL 104-191) and implementing regulations and must be protected in accordance with those provisions. Re-disclosure without patient consent or as otherwise permitted by law is prohibited.
Any unauthorized review, retransmission, use, printing, copying, retention, disclosure, distribution or the taking of any action in reliance upon this information by persons or entities other than the intended recipient is strictly prohibited and may be unlawful.
If you have received this message in error, please immediately advise the sender by reply email message to the sender and delete all copies of this message from your system without copying.
| Topic | Replies | Likes | Views | Participants | Last Reply |
|---|---|---|---|---|---|
| Future Diagnostics IOPTH Test System-Import Issue | 1 | 0 | 67 | ||
| CLIA Lab Director Site Visit Form/Checklist | 0 | 0 | 228 | ||
| Rapid molecular tests for Covid, FluAB, RSV and Strep A | 9 | 0 | 411 |